Scholars Central

Conference abstractPublished 7 Mar 2019

Immunogenic chemotherapy: The basic and the clinical application

Authors: Pedro Alejandro Lucero Diaz, Alejandro Camacho Hernandez, Jose Antonio Matute Briceno, Salvador Icedo Zamora, Juan Pablo Marquez Manriquez

Sonora Cancer Research Center (CICS), USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The two main cancer treatment modalities recognized for many years are cancer chemotherapy and radiotherapy. However, by performing dose-response and time-effect curves we can find clinically potential classic cytotoxic cancer chemotherapy that in the past was even fatal for some patients because the toxicity and some of them even required hospitalizations and internal medicine care. Examples of very useful drugs now recognized in many preclinical studies as an example 5-Fluorouracil, Cyclophosphamide, Adriamycin, Oxaliplatin, Carboplatin, Paclitaxel and many ones including old alkylant agents and new like temozolamide etc. So, with this in mind we performed in vitro several studies using 10-15% of the original dose used in the standard of care treatment. We found in this pilot clinical study just by adjusting the doses of Adriamycin, Oxaliplatin in particular showed significant clinical improvement in patients with challenge neoplasias such as refractory different subtypes of breast cancer, ovarian cancer, sarcomas and neurotumors in both adults and pediatric patients. Since 2011, the medical oncology initiated to recognize the power of training the right immune cells with different approaches including immunogenic chemotherapy to improve PFS and OS with limited clinical and economical toxicity. The concept of immunogenic chemotherapy occurs with some cancer classic cytotoxic chemotherapy are able to kill Cancer Stem Cells (CSCâ??s), augmenting the anti-tumor immune response mainly relay on CD8, Th1, and augmenting the â??flavorâ?� of the tumor cells and became more attractive by the mentioned cells. 16 patients were treated with 20 mg total of Adriamycin and 30 mg total dose of Oxaliplatin. We treated the patients having as end point the granzyme B ELISPOT and by cytotoxicity assays to evaluate the tumor cells death and correlate with the clinical by CT-Scan and the immunological assays. 16/10 patients improve statistically significant the Granzyme B production against four recall antigens and 10 tumor-associated antigens after one month of treatment. The treatment was well tolerated, and we continued the treatment until tumor progression. With one month of treatment 60 % of the patients undergo tumor reduction demonstrated by CT scan. Responder patients had high-production of Granzyme against a cocktail of four tumorassociated antigens (p=0.005). Clinical immunogenic chemotherapy with Adriamycin and Oxaliplatin will be a feasible protocol in combination with standard of care treatment, checkpoint inhibitors and multi-peptide active antigen specific immunotherapy in patients with good Karnofsky despite being refractory.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Pedro Alejandro Lucero Diaz”
  • BylineArticles whose byline prints “Alejandro Camacho Hernandez”
  • BylineArticles whose byline prints “Jose Antonio Matute Briceno”
  • BylineArticles whose byline prints “Salvador Icedo Zamora”
  • BylineArticles whose byline prints “Juan Pablo Marquez Manriquez”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels